Although these findings suggest differential efficacy between anti-PD-1 agents and anti-PD-L1 agents in ES-SCLC, a meta-analysis found no difference in clinical efficacy between anti-PD-1 agents and anti-PD-L1 agents [16]. Here, PDCD1 is linked to small cell lung carcinoma.